Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
Hand-out
Press Releases
Syndax Pharmaceuticals, Inc.  
November 5, 2024

Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting

– New monotherapy and combination data in acute leukemia further highlight revumenib's compelling clinical profile –

avatar profile Olean Times Herald

Olean Times Herald


Local & Social